ClinicalTrials.gg
CompletedNCT00086593Updated Oct 7, 2016

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

A Phase 3 interventional study of lamotrigine in Schizophrenia, sponsored by GlaxoSmithKline. Completed at 39 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-07.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Schizophrenia by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Schizophrenia · GlaxoSmithKline.

Enrollment
5th of 22
209 · median 46
Started
2004
with 3 others
Phase 3
2 of 23
none open now
Registered
3rd of 23
by date

Among the 23 studies in Schizophrenia by GlaxoSmithKline, this one is the 5th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2004, is one of 2 in phase 3, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 23 studies in Schizophrenia by GlaxoSmithKline is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Schizophrenia by GlaxoSmithKline as a file.
02

Study summary

This is a 12-week study for the treatment of chronic persistent symptoms in participants with schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics who fulfill the screening criteria will be randomized to receive either an FDA-approved drug or placebo in addition to the current treatment. Safety will be closely monitored through vital signs, various tests, and blood and urine samples.

03

Conditions studied

  • Schizophrenia

Keywords

  • adjunctive
  • atypical antipsychotics
  • add-on
  • Schizophrenia
  • psychosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with schizophrenia.
  • Exhibits persistent positive symptoms that have persisted for a minimum of 3 months prior to screening.
  • Continuously taking 1-2 specific atypical antipsychotics for a minimum of 3 months and must be on a stable dose for at least 1 month prior to entering the study.
  • Participant or a legal guardian is able to understand and sign the consent form.

Exclusion criteria

Exclusion criteria:

  • PANSS (Positive and Negative Syndrome Score) total score increases or decreases by more than 20% between the Screening and Baseline visits.
  • Predominant Axis I disorder other than schizophrenia within 6 months prior to screening.
  • History of or unstable medical disorder or treatment that would interfere with the study.
  • History of autistic disorder or another pervasive developmental disorder, organic brain disease, dementia, stroke, epilepsy or a history of seizures requiring treatment (this does not include febrile seizures as a child), or those who have suffered a traumatic head injury.
  • Taking psychotropic or primarily centrally active medication at screening.
  • Use of antidepressant medications or mood stabilizers within 1 month of screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
209 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the total score of the Positive and Negative Symptom Scale (PANSS) at Week 12.

    Time frame: 12 Weeks

Secondary outcomes

  1. - Efficacy - Change from baseline in PANSS positive symptoms at Week 12 - Change from baseline in the Scale for the Assessment of Negative Symptoms (SANS) at Week 12 - Change from baseline in PANSS general psychopathology symptoms at Week 12.

    Time frame: 12 Weeks

07

Study locations

39 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72201, United States
  • GSK Investigational Site
    Garden Grove, California 92845, United States
  • GSK Investigational Site
    Glendale, California 91206, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Pico Rivera, California 90660, United States
  • GSK Investigational Site
    San Diego, California 92126, United States
  • GSK Investigational Site
    Sherman Oaks, California 91403, United States
  • GSK Investigational Site
    Coral Springs, Florida 33065, United States
  • GSK Investigational Site
    Maitland, Florida 32751, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    North Miami, Florida 33161, United States
  • GSK Investigational Site
    Winter Park, Florida 32789, United States
  • GSK Investigational Site
    Niles, Illinois 60714, United States
  • GSK Investigational Site
    Oak Brook, Illinois 60523, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202-5200, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Staten Island, New York 10305, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Madison, Wisconsin 53711-2027, United States
  • GSK Investigational Site
    Edmonton, Alberta T5K 2J5, Canada
  • GSK Investigational Site
    Edmonton, Alberta T6G 2C8, Canada
  • GSK Investigational Site
    Kelowna, British Columbia V1W 4V5, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3E 3N4, Canada
  • GSK Investigational Site
    Miramichi, New Brunswick E1V 3G5, Canada
  • GSK Investigational Site
    Dartmouth, Nova Scotia B2Y 3S3, Canada
  • GSK Investigational Site
    Sydney, Nova Scotia B1S 2E8, Canada
  • GSK Investigational Site
    Burlington, Ontario L7N 3V2, Canada
  • GSK Investigational Site
    London, Ontario N6A 4G5, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5M 4N4, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 1X3, Canada
  • GSK Investigational Site
    Toronto, Ontario M6M 3Z5, Canada
  • GSK Investigational Site
    Windsor, Ontario N9C 3Z4, Canada
  • GSK Investigational Site
    Bedford, Bedfordshire MK42 9DJ, United Kingdom
  • GSK Investigational Site
    Cambridge, Cambridgeshire CB1 5EF, United Kingdom
  • GSK Investigational Site
    Glasgow, Lanarkshire G66 3UG, United Kingdom
  • GSK Investigational Site
    Coventry, Warwickshire CV2 2DX, United Kingdom
  • GSK Investigational Site
    Hull, HU6 7RX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Jul 2005 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2004
First posted
Jul 8, 2004
Start
May 2004
Primary completionActual
Jul 2005
CompletionActual
Jul 2005
Last update
Oct 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00086593
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 8, 2004
Start date
May 2004
Primary completion
Jul 2005
Completion
Jul 2005
Last update
Oct 7, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion